Tonix Pharmaceuticals Holding Corp.
TNXP
Rank in Stocks
#20876
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical firm primarily... Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical firm primarily operating in the clinical development stage. Its overarching mission involves the discovery, acquisition, advancement, and commercialization of novel therapeutic agents and diagnostic tools, all aimed at combating human illnesses and easing patient discomfort. The company boasts a comprehensive pipeline of potential treatments spanning several key medical fields: immunology, rare conditions, infectious diseases, and central nervous system (CNS) disorders. In the realm of immunology, Tonix is progressing with biologics designed to address organ transplant rejection, various autoimmune diseases, and certain forms of cancer. A prominent candidate here is TNX-1500, a humanized monoclonal antibody targeting CD40-ligand, which is being investigated for its utility in preventing both allograft and xenograft rejection, as well as in treating autoimmune disorders. Its rare disease initiatives include TNX-2900, a specific treatment candidate for Prader-Willi syndrome. The infectious disease segment features a diverse array of programs: TNX-801, a vaccine designed to offer protection against smallpox and monkeypox. TNX-1840 and TNX-1850, which are live virus vaccines based on the company's recombinant pox vaccine (RPV) platform, targeting COVID-19. TNX-3500, a small molecule antiviral drug for the treatment of acute COVID-19. TNX-102 SL, a small molecule medication under investigation for Long COVID, a persistent post-acute COVID-19 condition. Finally, the CNS portfolio encompasses both small molecules and biologics intended to manage pain, neurological conditions, psychiatric ailments, and addiction. Notably, TNX-102 SL is also in mid-Phase 3 development for alleviating fibromyalgia symptoms. Other CNS candidates include TNX-1900, which is being developed to prevent migraine headaches, and TNX-1300, a biologic aimed at treating cocaine intoxication. The company was established in 2007 and maintains its headquarters in Chatham, New Jersey.
Share Price
$4.49
Last synced: 2026-11-09
Market Cap
$77.01M
Change (1 day)
-5.27%
Change (1 year)
-74.39%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Tonix Pharmaceuticals Holding Corp. (TNXP)
Category
Healthcare
Operating Margin for Tonix Pharmaceuticals Holding Corp. (TNXP)
Operating Margin as of November 2026 TTM: -568.43%
According to Tonix Pharmaceuticals Holding Corp.'s latest financial reports, its current operating margin (TTM) is -568.43%. At the end of 2025 the company had an operating margin of -959.05%.
Operating Margin history for Tonix Pharmaceuticals Holding Corp. from 2008 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -568.43% | -40.73% |
| 2025 | -959.05% | -29.18% |
| 2024 | -1,354.28% | -11.13% |
| 2023 | -1,523.94% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
| 2012 | 0.00% | 0.00% |
| 2011 | 0.00% | 0.00% |
| 2010 | 0.00% | 0.00% |
| 2009 | 0.00% | 0.00% |
| 2008 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.07% |
US
|
|
| -149.01% | -99.74% |
US
|
|
| 25.57% | -100.04% |
AU
|
|
| 31.23% | -100.05% |
BE
|
|
| 29.35% | -100.05% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Tonix Pharmaceuticals Holding Corp.'s operating margin
What is Tonix Pharmaceuticals Holding Corp.'s operating margin?
Tonix Pharmaceuticals Holding Corp.'s operating margin is -568.43%, as of Nov 2026.
What was Tonix Pharmaceuticals Holding Corp.'s operating margin in 2025?
In 2025, Tonix Pharmaceuticals Holding Corp.'s operating margin was -959.05%, compared with -1,354.28% in 2024.
How has Tonix Pharmaceuticals Holding Corp.'s operating margin changed since 2020?
From 2020 to 2025, Tonix Pharmaceuticals Holding Corp.'s operating margin was highest in 2022 (0.00%) and lowest in 2023 (-1,523.94%).
How does Tonix Pharmaceuticals Holding Corp.'s operating margin compare with similar companies?
Tonix Pharmaceuticals Holding Corp.'s operating margin (-568.43%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.